Good MorningA much-needed market correction is underway and may not end soon. The sell-off was sparked by a sell-the-news event that has yet to play out. The news was the June CPI report, which was affirmed by the PCE price index; consumer inflation is falling closer to the FOMC's target of 2%, paving the path toward an interest rate cut. The significant detail is the interest rate cut, a move that will signal the easing of economic headwinds and a pivot for the market. That pivot will be into small and mid-cap names, driven by the expectation improving business conditions will drive growth and profits.
This week's risk is the FOMC. The FOMC is meeting on Tuesday and Wednesday and will release a fresh policy statement on Wednesday. The market is pricing in a rate cut for August and a high probability for a second in September. Still, the FOMC may hesitate to commit, inducing volatility in the market. The takeaway is that underlying economic conditions and outlook remain bullish; a stock market correction should result in a buy-the-dip opportunity and fresh all-time highs later this year. Featured: Boring, cheap, and paying 6% (Ad) 
|
Technology | | The earnings reports from Alphabet Inc. (NASDAQ: GOOGL) and Tesla Inc. (NASDAQ: TSLA) led technology stocks lower for the week. Some analysts are warning that the price action is due to an artificial intelligence (AI) bubble, but there could be other factors at play.
First, the second half of Jul... Read the Full Story |
|
From Our Partners | | Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade.
This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan. | | Claim your free options guide and start building real trading knowledge |
|
Technology | | The world of cryptocurrency is still a developing thesis, with some raging bulls on every coin out there and others calling the asset class a complete scam and Ponzi scheme. Whether one side is right or wrong is up for debate, but one thing remains true: investor and trader psychology and behavior.
... Read the Full Story |
|
Technology | | Owning stock gives investors a one-for-one behavior in the underlying stock, and that’s good enough when there is a longer timeframe. But it won’t cut it for big traders looking to quickly get a hit-and-run stock move.
That’s where stock options come in. They allow investors to ac... Read the Full Story |
|
From Our Partners | | More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily volume over 500,000 shares, and over $10 million in trailing revenue.
Only five stocks cleared every filter, spanning five different sectors. Two are profitable today, and one pays a substantial dividend.
The report also flags what could go wrong with each pick, including dilution and convertible debt. | | See the five stocks that survived this strict revenue screen |
|
Industrials | |
3M’s (NYSE: MMM) rebound is gaining momentum because of surprisingly good results. Today’s story is that repositioning efforts are taking hold and driving improved profitability while litigation risks dwindle. The takeaways from the Q2 report include better-than-expected top and bottom... Read the Full Story |
|
Markets | |
Some names in the retail and apparel sectors have made a splash in investors’ monitors in recent weeks, even months. Unfortunately, the attention is founded on seriously bearish price action, like the fact that shares of Lululemon Athletica Inc. (NASDAQ: LULU) are now trading at only 48% of ... Read the Full Story |
|
|
Technology | |
As earnings season unfolds and several mega-cap tech stocks, including members of the "Magnificent Seven," have reported, the overall market and tech sector have seen significant declines in recent weeks. The XLK technology sector ETF has dropped nearly 6% this month and is now down over 10% from ... Read the Full Story |
|
Technology | |
ServiceNow Inc. (NYSE: NOW), a leading provider of cloud-based software solutions, has recently made headlines with a notable 15% surge in its stock price following a strong earnings report.
This impressive gain brings its year-to-date performance to nearly 20%, and the stock has just broken o... Read the Full Story |
|
Healthcare | |
Molina Healthcare, Inc. (NYSE: MOH) is a leading provider of managed healthcare services, primarily focusing on government-sponsored programs such as Medicaid and Medicare. Molina Healthcare’s earnings report for the second quarter was released, and it sent shockwaves through the market, p... Read the Full Story |
|
Markets | |
AstraZeneca PLC (NASDAQ: AZN) is a United Kingdom-based healthcare firm and the sixth-largest pharmaceutical company in the world by market capitalization. So far, in 2024, the firm has outperformed the market and its sector, achieving a total return of 17%. The total return of the SPDR S&P ... Read the Full Story |
|
Healthcare | |
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics' earnings report for the second quarter of 2024 was impressive, capturing the attention of investors and ... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. | Should I Buy Edwards Lifesciences Stock? EW Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Edwards Lifesciences was last updated on Thursday, October 15, 2026 at 7:31 PM.
Edwards Lifesciences Bull Case -
Edwards Lifesciences Co. recently received FDA approval for its AUTUS size-adjustable pulmonary valve for pediatric patients, a development that expands the company's product portfolio into a new therapeutic area and demonstrates its continued innovation in structural heart disease treatments.
-
The company reported strong financial performance in its most recent quarter, with revenue of $1.74 billion, which exceeded the consensus estimate of $1.70 billion and represented a 13.6% year-over-year increase, indicating robust demand for its medical technologies.
-
Wall Street analysts maintain a positive outlook on the stock, with a consensus rating of Moderate Buy and a target price of $100.27, which suggests potential upside from the current stock price of $88.05 as of October 15, 2026.
-
Edwards Lifesciences Co. has a low debt-to-equity ratio of 0.06, reflecting a strong balance sheet and financial stability that can support long-term growth initiatives and provide a buffer against economic downturns.
-
The company is scheduled to host an investor event on November 2, 2026, including a live Q&A with physicians and management, which may provide additional insights into its strategic direction and product pipeline, potentially boosting investor confidence.
Edwards Lifesciences Bear Case -
Insiders have been consistently selling shares, with 24 sales and no purchases in the past six months, including recent transactions by executives such as VP Daniel Lippis and SVP Andrew M. Dahl, which may signal a lack of confidence in the stock's near-term performance.
-
Several institutional investors, including Ninety One UK Ltd and Ninety One North America Inc., have reduced their positions in Edwards Lifesciences Co. during the third quarter, with Ninety One UK Ltd selling 393,827 shares and Ninety One North America Inc. decreasing its stake by 5.6%, indicating potential institutional skepticism.
-
The stock's price-to-earnings ratio of 30.76 is relatively high compared to some peers, which may limit upside potential if earnings growth does not accelerate to justify the valuation, especially given the company's guidance for FY 2026 EPS of $2.950 to $3.050.
-
Short interest in Edwards Lifesciences Co. has increased slightly, with 9,538,735 shares shorted as of September 30, 2026, representing a 4.96% month-to-month increase, which could indicate bearish sentiment among some market participants.
-
The company's dividend yield is 0.00%, meaning it does not provide income to investors, which may be a drawback for those seeking regular cash flow from their investments, particularly in a market where dividend-paying stocks are often favored for stability.
| | View Today's Stock Pick |
|
